当前位置: X-MOL 学术Acta Neuropathol. Commun. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
Acta Neuropathologica Communications ( IF 7.1 ) Pub Date : 2020-11-23 , DOI: 10.1186/s40478-020-01069-3
Vanessa Laversenne 1 , Sameer Nazeeruddin 1 , Emma C Källstig 1 , Philippe Colin 1, 2 , Christel Voize 1 , Bernard L Schneider 1, 2
Affiliation  

The brain pathology of Alzheimer’s disease (AD) is characterized by the misfolding and aggregation of both the amyloid beta (Aβ) peptide and hyperphosphorylated forms of the tau protein. Initial Aβ deposition is considered to trigger a sequence of deleterious events contributing to tau pathology, neuroinflammation and ultimately causing the loss of synapses and neurons. To assess the effect of anti-Aβ immunization in this context, we generated a mouse model by overexpressing the human tau protein in the hippocampus of 5xFAD mice. Aβ plaque deposition combined with human tau overexpression leads to an array of pathological manifestations including the formation of tau-positive dystrophic neurites and accumulation of hyperphosphorylated tau at the level of neuritic plaques. Remarkably, the presence of human tau reduces microglial clustering in proximity to the Aβ plaques, which may affect the barrier role of microglia. In this mouse model, continuous administration of anti-Aβ antibodies enhances the clustering of microglial cells even in the presence of tau. Anti-Aβ immunization increases plaque compaction, reduces the spread of tau in the hippocampal formation and prevents the formation of tau-positive dystrophic neurites. However, the treatment does not significantly reduce tau-induced neurodegeneration in the dentate gyrus. These results highlight that anti-Aβ immunization is able to enhance microglial activity around neuritic plaques, mitigating part of the tau-induced pathological manifestations.

中文翻译:

与神经炎斑块结合的抗 Aβ 抗体可增强小胶质细胞活性并减轻 tau 蛋白病理

阿尔茨海默病 (AD) 的脑病理特征在于淀粉样蛋白 β (Aβ) 肽和 tau 蛋白的过度磷酸化形式的错误折叠和聚集。最初的 Aβ 沉积被认为会触发一系列有害事件,导致 tau 病理学、神经炎症,并最终导致突触和神经元的丧失。为了评估在这种情况下抗 Aβ 免疫的效果,我们通过在 5xFAD 小鼠的海马中过表达人 tau 蛋白来生成小鼠模型。Aβ 斑块沉积与人 tau 过表达相结合导致一系列病理表现,包括 tau 阳性营养不良性神经突的形成和神经炎斑块水平过度磷酸化 tau 的积累。值得注意的是,人类 tau 蛋白的存在减少了 Aβ 斑块附近的小胶质细胞聚集,这可能会影响小胶质细胞的屏障作用。在这个小鼠模型中,即使在 tau 存在的情况下,连续施用抗 Aβ 抗体也会增强小胶质细胞的聚集。抗 Aβ 免疫可增加斑块压实,减少 tau 在海马形成中的扩散,并防止 tau 阳性营养不良性神经突的形成。然而,该治疗并没有显着减少 tau 诱导的齿状回神经变性。这些结果强调,抗 Aβ 免疫能够增强神经炎斑块周围的小胶质细胞活性,减轻部分 tau 诱导的病理表现。即使在 tau 存在的情况下,连续施用抗 Aβ 抗体也会增强小胶质细胞的聚集。抗 Aβ 免疫可增加斑块压实,减少 tau 在海马形成中的扩散,并防止 tau 阳性营养不良性神经突的形成。然而,该治疗并没有显着减少 tau 诱导的齿状回神经变性。这些结果强调,抗 Aβ 免疫能够增强神经炎斑块周围的小胶质细胞活性,减轻部分 tau 诱导的病理表现。即使在 tau 存在的情况下,连续施用抗 Aβ 抗体也会增强小胶质细胞的聚集。抗 Aβ 免疫可增加斑块压实,减少 tau 在海马形成中的扩散并防止 tau 阳性营养不良性神经突的形成。然而,该治疗并没有显着减少 tau 诱导的齿状回神经变性。这些结果强调,抗 Aβ 免疫能够增强神经炎斑块周围的小胶质细胞活性,减轻部分 tau 诱导的病理表现。该治疗不会显着减少 tau 诱导的齿状回神经变性。这些结果强调,抗 Aβ 免疫能够增强神经炎斑块周围的小胶质细胞活性,减轻部分 tau 诱导的病理表现。该治疗不会显着减少 tau 诱导的齿状回神经变性。这些结果强调,抗 Aβ 免疫能够增强神经炎斑块周围的小胶质细胞活性,减轻部分 tau 诱导的病理表现。
更新日期:2020-11-23
down
wechat
bug